This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Threshold Pharmaceuticals, Inc.

Drug Names(s): flortanidazole (18F), [F-18]HX4

Description: [18F]HX4 [flortanidazole (18F)] is a novel investigational tumor hypoxia tracer to potentially identify and quantify the degree of hypoxia in tumors in vivo.

Deal Structure: [18F]HX4 was originally developed by Siemens Molecular Imaging.

Siemens and Threshold
In March 2013, Siemens and Threshold entered into a global agreement by which Threshold will acquire [18F]HX4. Under the terms of the agreement, Siemens will transfer ownership and existing preclinical, clinical and manufacturing data related to [18F]HX4 to Threshold. Threshold will be responsible for the development and commercialization of [18F]HX4. Financial terms of the agreement were not disclosed.

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug